Raymond James Financial Inc. purchased a new stake in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 87,920 shares of the company's stock, valued at approximately $1,233,000. Raymond James Financial Inc. owned about 0.21% of SI-BONE at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the business. Proficio Capital Partners LLC acquired a new position in SI-BONE in the fourth quarter valued at $155,000. Mainstream Capital Management LLC acquired a new position in SI-BONE in the 4th quarter valued at about $53,000. Charles Schwab Investment Management Inc. raised its stake in SI-BONE by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 321,263 shares of the company's stock valued at $4,504,000 after acquiring an additional 6,171 shares during the last quarter. VELA Investment Management LLC lifted its position in SI-BONE by 23.8% during the 4th quarter. VELA Investment Management LLC now owns 122,671 shares of the company's stock worth $1,720,000 after acquiring an additional 23,592 shares during the period. Finally, Versor Investments LP purchased a new position in shares of SI-BONE in the 4th quarter valued at approximately $185,000. Institutional investors and hedge funds own 98.11% of the company's stock.
SI-BONE Stock Performance
SI-BONE stock remained flat at $13.47 during midday trading on Monday. The company's stock had a trading volume of 492,285 shares, compared to its average volume of 360,497. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The company has a market capitalization of $571.84 million, a price-to-earnings ratio of -14.64 and a beta of 1.02. The company's fifty day simple moving average is $16.09 and its 200 day simple moving average is $14.69.
SI-BONE (NASDAQ:SIBN - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $49.00 million during the quarter, compared to analysts' expectations of $48.87 million. Equities analysts predict that SI-BONE, Inc. will post -0.78 earnings per share for the current year.
Insider Transactions at SI-BONE
In related news, insider Anthony J. Recupero sold 3,311 shares of the business's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.15, for a total value of $46,850.65. Following the sale, the insider now directly owns 284,555 shares in the company, valued at $4,026,453.25. The trade was a 1.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total transaction of $44,229.92. Following the completion of the sale, the senior vice president now directly owns 244,878 shares in the company, valued at approximately $3,462,574.92. The trade was a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,776 shares of company stock valued at $96,644 in the last quarter. 3.90% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. Needham & Company LLC upped their price target on SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Truist Financial restated a "buy" rating and issued a $22.00 target price (up previously from $18.00) on shares of SI-BONE in a research note on Tuesday, February 25th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of SI-BONE in a research note on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $24.40.
View Our Latest Research Report on SI-BONE
About SI-BONE
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
Featured Articles
Before you consider SI-BONE, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.
While SI-BONE currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
